In another subtype of prostate cancer cells (e.g., PC-82 and CWR22), AR is expressed and has acquired a gain-of-function such that it no longer inhibits but now stimulates proliferation when activated by physiological levels of androgen [13]. The gene discussed is AR; the disease is prostate carcinoma.